Key result
Gemcitabine-based chemotherapy does not increase venous or arterial thromboembolic risk versus non-gemcitabine therapy.
Why the study?
Gemcitabine has been associated with an increased risk of arterial and venous thromboembolic events, but the overall risk remains unclear in patients with solid tumours.
Does gemcitabine-based chemotherapy increase the risk of venous and arterial thromboembolic events in patients with solid tumours?
Population
4,845 patients with solid tumours from 19 prospective randomized controlled phase II and III trials
Comparison
Gemcitabine-based chemotherapy vs non-gemcitabine-based chemotherapy
Design
Systematic review and meta-analysis of randomized controlled trials
Authors
Loading...
Gemcitabine use need not prompt extra thromboprophylaxis; reinforces meta-analytic safety data versus other regimens.
Meta-Analysis (n=4,845)
Does gemcitabine-based chemotherapy increase the risk of venous and arterial thromboembolic events in patients with solid tumours?
Odds Ratio: 1.56 (95% CI 0.86–2.83)
p-value: p=0.15
Gemcitabine-based chemotherapy does not significantly increase the risk of venous and arterial thromboembolic events in patients with solid tumors.
Qi et al. (2013) conducted a meta-analysis in Solid tumours (n=4,845). Gemcitabine based chemotherapy vs. Non-gemcitabine based chemotherapy was evaluated on Venous thromboembolic events (VTEs) (OR 1.56, 95% CI 0.86-2.83, p=0.15). Gemcitabine-based chemotherapy did not significantly increase the risk of venous (OR 1.56; 95% CI 0.86-2.83; P=0.15) or arterial thromboembolic events compared with non-gemcitabine therapy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: